Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer

British Journal of Cancer

Volumn 81, Issue 4, 1999, Pages 609-615

  Zoli, W ^a   Ricotti, L ^b   Dal Susino, M ^b   Barzanti, F ^b   Frassineti, G L ^a   Folli, S ^a   Tesei, A ^b   Bacci, F ^a   Amadori, D ^a  

^a MORGAGNI PIERANTONI HOSPITAL   (Italy)

^b ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

Author keywords

Combination regimens; Docetaxel; Gemcitabine; NSCLC cell lines; NSCLC primary cultures; Preclinical therapy

Indexed keywords

CARBOPLATIN; CELL DNA; CISPLATIN; DOCETAXEL; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CARCINOID; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0032885543     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690737     Document Type: Article

References (34)

1. Amadori D, Frassineti GL, Zoli W, Milandri C, Tienghi A, Ravaioli A, Gentile A and Salzano E (1996) A phase I/II study of sequential doxorubicin and paclitaxel treatment of advanced breast cancer. Semin Oncol 23 (Suppl 11): S16-S22
2. Amadori D, Frassineti GL, De Matteis A, Mustacchi G, Santoro A, Cariello S, Ferrari M, Nascinben O, Nanni O, Lombardi A, Scarpi E and Zoli W (1998) Modulating effect of Ionidamine on response to doxorubicin in metastatic breast cancer patients: results from a multicenter prospective randomized trial. Breast Cancer Res Treat 49: 209-217
3. Befani CP (1998) Single agents in the second-line treatment of non-small cell lung cancer. Semin Oncol 25 (Suppl 8): S10-S14
4. Boyer MJ (1998) New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience. Chest 113 (suppl 1): S24-S27
5. Crino L, Mosconi AM, Scagliotti G, De Marinis F, Darwish S, Calandri C, Adamo V, Scarcella L, Pucci F and Tonato M (1997) Salvage therapy with gemcitabine (GEM) in pretreated, advanced non-small cell lung cancer (NSCLC). Proc Annu Meet Soc Clin Oncol 16: 1603
6. Citro G, Cucco C, Verdiana A and Zupi G (1991) Reversal of adriamycin resistance by Ionidamine in a human breast cancer cell line. Br J Cancer 64: 534-536
7. Cortes-Funes H, Martin C, Abrat R and Lund B (1997) Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer. Anticancer Drugs 8: 582-587
8. De Lena M, Lorusso V, Bottalico C, Brandi M, De Mitrio A, Catino A, Guida M, Latorre A, Leone B, Vallejo C and Gargano G (1997) Revertant and potentiating activity of Ionidamine in patients with ovarian cancer previously treated with platinum. J Clin Oncol 15: 3208-3213
9. Dogliotti L, Berruti A, Buniva T, Zola P, Bau MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M and Perroni D (1996) Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer results from a multicenter prospective randomized trial. J Clin Oncol 14: 1165-1172
10. Drewinko B, Loo TL, Brown B, Gottlieb JA and Freireich EJ (1976) Combination chemotherapy in vitro with adriamycin. Observations of additive, antagonistic and synergistic effects when used in two-drug combinations on cultured human lymphoma cells. Cancer Biochem Biophys I: 187-195
11. Feigal EG, Christian M and Cheson B (1993) New chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 20: 185-201
12. Fischel JL, Etienne MC, Formento P and Milano G (1998) Search for the optimal schedule for the oxaliplatin/5-fluoruracil association modulated or not by folinic acid: preclinical data. Clin Cancer Res 4: 2529-2535
13. Frassineti GL, Zoli W, Silvestro L, Serra P, Milandri C, Tienghi A, Gianni L, Gentile A, Salzano E and Amadori D (1997) Paclitaxel plus doxorubicin in breast cancer: an Italian expeirence. Semin Oncol 24: (Suppl 17) S19-S25
14. Gasperi-Campani A, Roncuzzi L, Ricotti L, Lenzi L, Gruppioni R, Sensi A, Zini M, Zoli W and Amadori D (1998) Molecular and biological features of two new human cell lines from squamous and adenocarcinoma of the lung. Cancer Gen Cytogen 107: 11-20
15. Georgoulias V, Kourousis C, Kakolyris S, Androulakis N, Dimopoulos MA, Papadakis E, Kotsakis T, Vardakis N, Kalbakis K, Meramveliotakis N and Hatzidaki D (1997a). Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. Semin Oncol 24 (Suppl 12): S61-S66
16. Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Dimopoulos MA, Bouros D, Papadimitriou C, Hatzakis K, Heras P, Kalbakis K, Kotsakis T, Vardakis N, Meramveliotakis N and Hatzidaki D (1997b). Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results. Semin Oncol 24 (Suppl 14): S22-S25
17. Georgoulias V, Kourousis C, Androulakis N, Kakolyris S, Dimopoulos MA, Papadakis E, Bouros D, Apostolopaulou F, Papadimitriou C, Angelidou A, Hatzakis K, Kalbakis K, Kotsakis T, Vardakis N and Vlachonicolis J (1999) Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. J Clin Oncol 17: 914-920
18. Hahn SM, Liebman JE, Cook J, Fisher J, Goldspiel B, Venzon D, Mitchell JB and Kaupfman D (1993) Taxol in combination with doxorubicin or etoposide. Cancer 72: 2705-2711
19. Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB (1990) Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422
20. Le Chevalier T (1996) Single-agent activity of gemeitabine in advanced non-small cell lung canter. Semin Oncol 13 (Suppl 10): 36-42
21. Natale RB (1998) Experience with new chemotherapeutic agents in non-small cell lung cancer. Chest 113 (Suppl 1): 32S-39S
22. Non-small Cell Lung Cancer Collaborative Group (1995) Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909
23. Peters GJ, Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM and Braakhuis BJM (1995) Interaction between cisplatin and gemeitabine in vitro and in vivo. Semin Oncol 22 (Suppl 11): 72-79
24. Savini S, Zoli W, Nanni O, Volpi A, Frassineti GL, Magni E, Flamigni A, Amadori A and Amadori D (1992) In vitro potentiation by Ionidamine of the cytotoxic effect of adriamycin on primary and established breast cancer cell lines. Breast Cancer Res Treat 24: 27-34
25. Silvestrini R, Gornati D, Zaffaroni N, Bearzatto A and De Marco C (1997) Modulation by Ionidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells. Breast Cancer Res Trent 42: 103-112
26. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren J, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxic assay for anticancer-drug screening. J Natl Cancer Inst 13: 1107-1112
27. Spiridonidis CH, Laufman LR, Jones J, Rhodes VA, Wallace K and Nicol S (1998) Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 16: 3866-3873
28. Takada M, Negoro S, Kudo S, Furuse K, Nishikawa H, Takada Y, Kamei T, Niitani H and Fukuoka M (1998) Activity of gemeitabine in non-small-cell lung cancer: results of the Japan gemeitabine group (A) phase II study. Cancer Chemother Pharmacol 41: 217-222
29. Theodossiou C, Cook JA, Fisher J, Tongue D, Liebmann JE, Russo A and Mitchell JB (1998) Interaction of gemcitabine with paclitaxel and cisplatin in human tumour cell lines. Int J Oncol 12: 825-832
30. Van Moorsel CJA, Veerman G, Vermoken JB, Kroep JR, Van Groeningen CJ, Voorn DA, Catik A, Gall HE, Eeltink CM, Van der Vijgh WJF, Pinedo HM and Peters GJ (1998) Schedule dependent changes in the pharmacokinetics (PK) and pharmacodynamics of gemeitabine (GEM) and cisplatin (CP) in patients (pts) with solid tumors. Proc Am Assoc Cancer Res 39: 188
31. Van Moorsel CJA, Pinedo JIM, Veerman G, Guechev A, Smid K, Loves WJ, Vermoken JB, Postmun PE and Peters GJ (1999) Combination chemotherapy studies with gemeitabine and etoposide in non small cell lung and ovarian cancer cell lines. Biochem Pharmacol 15; 57 (4): 407-415
32. Kroep JR, Voorn DA, Van Moorsel CJA, Giaccone G, Postmus PE, Rosing H, Beijnen JH, Gall H, Smit EF, Van Groeningen CJ, Pinedo HM and Peters GJ (1998) Pharmakinetics interaction between paclitaxel (TAX) and gemcitabine (GEM) in patients (pts) with non-small-cell lung cancer (NSCLC). Proc Am Assoc Cancer Res 39: 188
33. Villa R, Zaffaroni N, Orlandi L, Costa A, Veronese S, Vaglini N and Silvestrini R (1992) Reliability of a primary system to test cytotoxic drug activity in human malignant melanoma. Int J Oncol 1: 619-624
34. Zoli W, Ricotti L, Barzanti L, Dal Susino M, Frassineti GL, Milandri C, Casadei Giunchi D and Amadori D (1999) Schedule-dependent interaction of doxorubicin, paclitaxel and gemeitabine in human breast cancer cell lines. Int J Cancer 80: 413-416